{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:04:38Z","timestamp":1768975478261,"version":"3.49.0"},"reference-count":388,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,4,26]],"date-time":"2002-04-26T00:00:00Z","timestamp":1019779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B\u2010CLL is the most common adult leukemia in the Western world. It is a neoplasia of mature looking B\u2010monoclonal lymphocytes co\u2010expressing the CD5 antigen (involving the blood, the bone marrow, the lymph nodes and related organs). Much new information about the nature of the neoplastic cells, including chromosomal and molecular changes as well as mechanisms participating in the survival of the leukemic clone have been published recently, in an attempt to elucidate the biology of the disease and identify prognostic subgroups. For the time being, clinical stage based on Rai and Binet staging systems remains the strongest predictor of prognosis and patients' survival, and therefore it affects treatment decisions. In the early stages treatment may be delayed until progression. When treatment is necessary according to well\u2010established criteria, there are nowadays many different options. Chlorambucil has been the standard regimen for many years. During the last decade novel modalities have been tried with the emphasis on fludarabine and 2\u2010chlorodeoxyadenosine and their combinations with other drugs. Such an approach offers greater probability of a durable complete remission but no effect on overall survival has been clearly proven so far. Other modalities, included in the therapeutic armamentarium, are monoclonal antibodies, stem cell transplantation (autologous or allogeneic) and new experimental drugs. Supportive care is an important part of patient management and it involves restoring hypogammaglobulinemia and disease\u2010related anemia by polyvalent immunoglobulin administration and erythropoietin respectively. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.696","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T20:29:21Z","timestamp":1031257761000},"page":"103-146","source":"Crossref","is-referenced-by-count":32,"title":["B\u2010chronic lymphocytic leukemia: practical aspects"],"prefix":"10.1002","volume":"20","author":[{"given":"Gerassimos A.","family":"Pangalis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria N.","family":"Dimopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina P.","family":"Siakantaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora N.","family":"Kontopidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,26]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"11","volume-title":"Chronic Lymphocytic Leukemia","author":"Linet MS","year":"1988"},{"key":"e_1_2_1_3_2","first-page":"71","article-title":"Relative frequency and mortality rate of various types of leukemia in Japan","volume":"60","author":"Nishiyama H","year":"1969","journal-title":"Gann"},{"key":"e_1_2_1_4_2","unstructured":"Report of the Committee on the Biological Effects of Ionizing Radiation.The Effects on Populations of Exposure to Low Levels of Ionizing Radiation(The 1980 BEIR Report). National Academy of Sciences National Research Council: Washington DC 1980."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2307\/3578404"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.3.435"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909209032771"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90183.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1984)54:4<702::AID-CNCR2820540418>3.0.CO;2-U"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V64.3.642.642","article-title":"Bone marrow histologic pattern. The best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases","volume":"64","author":"Rozman C","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ajcp\/99.4.402","article-title":"Malignant disorders of small lymphocytes. Small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and chronic lymphocytic leukemia: their clinical and laboratory relationship","volume":"99","author":"Pangalis GA","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_1_13_2","first-page":"104","article-title":"B\u2010chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders","volume":"36","author":"Pangalis GA","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.8.1901.1901"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059151"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103401"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103402"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood.V78.6.1545.1545","article-title":"Presenting features and prognosis of chronic lymphocytic leukemia in younger adults","volume":"78","author":"Montserrat E","year":"1991","journal-title":"Blood"},{"key":"e_1_2_1_19_2","first-page":"1232","article-title":"Prognostic features and survival in young adults with early\/intermediate chronic lymphocytic leukemia (B\u2010CLL): a single institution study","volume":"7","author":"Dhodapkar M","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.448"},{"key":"e_1_2_1_21_2","first-page":"107","article-title":"Chronic lymphocytic leukemia in the young patient","volume":"25","author":"de Lima M","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900120105"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb05845.x"},{"issue":"1","key":"e_1_2_1_24_2","first-page":"828a","article-title":"Tonsilar involvement in Rai 0 B\u2010chronic lymphocytic leukemia (B\u2010CLL) patients. A histologic, immunophenotypic and adhesion molecule study","volume":"89","author":"Angelopoulou MK","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1984.tb00899.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199608000-00009"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1478.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909093723"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800770427"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.7.1639.1639"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870215)59:4<767::AID-CNCR2820590417>3.0.CO;2-6"},{"key":"e_1_2_1_33_2","first-page":"173","volume-title":"Chronic Lymphocytic Leukemia","author":"Pangalis GA","year":"1988"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.449988.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.6.562"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000205747"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<208::AID-AJH2>3.0.CO;2-E"},{"key":"e_1_2_1_38_2","first-page":"334","article-title":"Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution","volume":"79","author":"Mauro FR","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01380.x"},{"key":"e_1_2_1_40_2","first-page":"178","article-title":"Adhesion molecules in B\u2010chronic lymphoproliferative disorders","volume":"36","author":"Angelopoulou MK","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197703)39:3<999::AID-CNCR2820390302>3.0.CO;2-R"},{"key":"e_1_2_1_42_2","first-page":"227","volume-title":"Benign and Malignant lymphadenopathies: Clinical and Laboratory Diagnosis","author":"Matutes E","year":"1993"},{"key":"e_1_2_1_43_2","first-page":"1","volume-title":"Malignant Lymphomas Other Than Hodgkin's Disease","author":"Muller\u2010Hermelink HK","year":"1988"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197801)41:1<283::AID-CNCR2820410140>3.0.CO;2-H"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008278706002"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0385-8"},{"key":"e_1_2_1_48_2","first-page":"193","volume-title":"Chronic Lymphocytic Leukemia","author":"Lampert IA","year":"1988"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331606"},{"key":"e_1_2_1_50_2","first-page":"249","volume-title":"American Society of Hematology Education Program Book, Hematology","author":"Caligaris\u2010Cappio F","year":"1999"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02989583"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(97)10008-7"},{"key":"e_1_2_1_53_2","first-page":"11","article-title":"Molecular biology of chronic lymphocytic leukemia","volume":"25","author":"Reed JC","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.399"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V87.7.2615.bloodjournal8772615","article-title":"B\u2010chronic lymphocytic leukemia: A malignancy of anti\u2010self B\u2010cells","volume":"87","author":"Caligaris\u2010Cappio F","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_56_2","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood.V89.11.4153","article-title":"Differential rates of somatic hypermutation in VH genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities","volume":"89","author":"Oscier DG","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_2_1_58_2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle RN","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045711"},{"key":"e_1_2_1_60_2","first-page":"1966","article-title":"Expression of the immunoglobulin\u2010associated protein B29 in B\u2010cell disorders with the monoclonal antibody SN8 (CD79b)","volume":"10","author":"Zomas AP","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_61_2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V93.7.2327","article-title":"An alternatively spliced form of CD79b gene may account for altered B\u2010cell receptor expression in B\u2010chronic lymphocytic leukemia","volume":"93","author":"Alfarano A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_62_2","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V93.11.3587","article-title":"Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies","volume":"93","author":"Wickremasinghe RG","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3379"},{"key":"e_1_2_1_64_2","first-page":"S22","article-title":"Bcl\u20102 family proteins in deregulation of apoptosis and chemoresistance in B\u2010CLL","volume":"39","author":"Reed JC","year":"1997","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1820.1820"},{"key":"e_1_2_1_66_2","first-page":"1227","article-title":"Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia","volume":"9","author":"Panayiotidis P","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.11.4342.411k39_4342_4349"},{"key":"e_1_2_1_69_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/(SICI)1097-0215(19960422)69:2<114::AID-IJC8>3.0.CO;2-3","article-title":"Bcl\u20102, Bax and p53 expression in B\u2010CLL in relation to in vitro survival and clinical progression","volume":"69","author":"Agular\u2010Santelises M","year":"1996","journal-title":"Int J Cancer"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609093434"},{"key":"e_1_2_1_71_2","first-page":"339","article-title":"Autocrine or paracrine models of cytokine production and utilization in B\u2010cell chronic lymphocytic leukemia","volume":"30","author":"Foa R","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1997.17"},{"key":"e_1_2_1_73_2","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382","article-title":"Interleukin\u20108 induces the accumulation of B\u2010cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion","volume":"87","author":"Francia Di Celle P","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_74_2","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.V87.8.3327.bloodjournal8783327","article-title":"Interleukin\u201015 promotes the growth of leukemic cells of patients with B\u2010cell chronic lymphoproliferative disorders","volume":"87","author":"Trentin L","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2107.x"},{"key":"e_1_2_1_76_2","first-page":"102","volume-title":"Sixth Meeting of the European Haematology Association Educational Book","author":"Caligaris\u2010Cappio F","year":"2001"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(00)79005-1"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0997-984"},{"key":"e_1_2_1_79_2","first-page":"3","article-title":"Immunophenotypic analysis of chronic lymphoid leukemias","volume":"1","author":"Catovsky D","year":"1997","journal-title":"Rev Clin Exp Hematol"},{"key":"e_1_2_1_80_2","first-page":"6","article-title":"Clinical utility of flow cytometry in the chronic lymphoid leukemias","volume":"25","author":"DiGiuseppe JA","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921115)70:10<2436::AID-CNCR2820701009>3.0.CO;2-C"},{"key":"e_1_2_1_82_2","first-page":"1640","article-title":"The immunological profile of B\u2010cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"10","author":"Matutes E","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08277.x"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.7.1795.1795"},{"key":"e_1_2_1_85_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.V82.4.1239.1239","article-title":"Phenotypic markers and BCL\u20101 gene rearrangements in B\u2010cell chronic lymphocytic leukemia: A cancer and leukemia group B study","volume":"82","author":"Newman RA","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.402686.x"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(96)00253-1"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/345093a0"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050350"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_1_91_2","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood.V88.8.3109.bloodjournal8883109","article-title":"Minimal region of loss at 13q14 in B\u2010cell chronic lymphocytic leukemia","volume":"88","author":"Bullrich F","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_92_2","first-page":"171","article-title":"Genetics of small lymphocyte disorders","volume":"36","author":"Panayiotidis P","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05180.x"},{"key":"e_1_2_1_94_2","first-page":"705","article-title":"Prognostic value of biological variables in B\u2010cell chronic lymphocytic leukemia. Can we improve upon clinical parameters?","volume":"82","author":"Molica S","year":"1997","journal-title":"Haematologica"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401561"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400818"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00661.x"},{"key":"e_1_2_1_98_2","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/blood.V79.7.1796.1796","article-title":"Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hynbridization to interphase cell: a simple and sensitive method","volume":"79","author":"Anastasi J","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199009133231105"},{"key":"e_1_2_1_100_2","first-page":"19","article-title":"Cytogenetics in chronic lymphocytic leukemia","volume":"25","author":"Juliusson G","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06367.x"},{"key":"e_1_2_1_102_2","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood.V81.10.2702.2702","article-title":"Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia","volume":"81","author":"Escudier SM","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10117-4"},{"key":"e_1_2_1_104_2","first-page":"24","article-title":"ATM mutations in B\u2010cell chronic lymphocytic leukemia","volume":"59","author":"Bullrich F","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_105_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V94.2.748","article-title":"Somatic ATM mutations indicate a pathogenic role of ATM in B\u2010cell chronic lymphocytic leukemia","volume":"94","author":"Schaffner C","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_106_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V89.7.2516","article-title":"11q deletions identify a new subset of B\u2010cell chronic lymphocytic leukaemia characterized by extensive nodal involvement and inferior prognosis","volume":"89","author":"Dohner H","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00095-7"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401499"},{"key":"e_1_2_1_109_2","first-page":"107","volume-title":"Sixth Meeting of the European Haematology Association, Educational Book","author":"Stilgenbauer S","year":"2001"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1704.x"},{"key":"e_1_2_1_111_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0145-2126(96)00076-8","article-title":"Expression of adhesion molecules in 113 patients with B\u2010cell chronic lymphocytic leukemia: relationship with clinico\u2010prognostic features","volume":"21","author":"Domingo A","journal-title":"Leuk Res 197"},{"key":"e_1_2_1_112_2","first-page":"104","article-title":"Expression of adhesion molecules in chronic B\u2010cell lymphoproliferative disorders","volume":"83","author":"Lucio PJ","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_1_113_2","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V81.10.2679.2679","article-title":"Adhesion molecule expression on B\u2010cell lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets","volume":"81","author":"De Rossi G","year":"1993","journal-title":"Blood"},{"issue":"2","key":"e_1_2_1_114_2","first-page":"287","article-title":"An adhesion molecule (AM) study of blood and tonsilar lymphocytes in Rai 0 B\u2010chronic lymphocytic low grade non\u2010Hodgkin's lymphomas (LGNHL)","volume":"93","author":"Angelopoulou MK","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_2_1_115_2","first-page":"522a","article-title":"The adhesion molecule profile of mantle cell lymphoma (MCL) vs B\u2010chronic lymphocytic leukemia (B\u2010CLL)","volume":"90","author":"Angelopoulou MK","year":"1997","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_116_2","first-page":"249b","article-title":"The adhesion molecule profile (AM) of B\u2010chronic lymphocytic leukemia (B\u2010CLL). Correlation with disease activity","volume":"90","author":"Angelopoulou MK","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4"},{"issue":"2","key":"e_1_2_1_118_2","first-page":"117","article-title":"Immunoglobulin disorders at diagnosis and course of B\u2010chronic lymphocytic leukemia (B\u2010CLL) patients","volume":"93","author":"Vassilakopoulos TP","year":"1996","journal-title":"Br J Haematol"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204315"},{"key":"e_1_2_1_120_2","first-page":"23","volume-title":"Immunoglobulins: Extending the Horizon","author":"Vassilakopoulos TP","year":"1994"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1159\/000205593"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.147.9.1614"},{"key":"e_1_2_1_123_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ajcp\/87.3.385","article-title":"Monoclonal proteins in chronic lymphocytic leukemia","volume":"87","author":"Noel P","year":"1987","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_1_124_2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood.V84.4.1216.1216","article-title":"High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B\u2010cell lymphocytic leukemia","volume":"84","author":"Beaume A","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_125_2","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V81.10.2475.2475","article-title":"Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune disease","volume":"81","author":"Kipps TJ","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_126_2","volume-title":"5th International Workshop on Chronic Lymphocytic Leukemia","author":"Lymberi PP","year":"1991"},{"key":"e_1_2_1_127_2","first-page":"403","article-title":"Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL)","volume":"30","author":"De Rossi G","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.39.7.713"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830430406"},{"key":"e_1_2_1_130_2","first-page":"304","article-title":"Fludarabine therapy for lymphoid malignancies is associated with hemolytic anemia","volume":"13","author":"Byrd JC","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1885"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00933.x"},{"key":"e_1_2_1_133_2","article-title":"Differential diagnosis of the leukemic chronic lymphoproliferative disorders","author":"Pangalis GA","journal-title":"Haema"},{"key":"e_1_2_1_134_2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V90.8.2863","article-title":"Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancy","volume":"90","author":"Jenning CD","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_135_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01200.x"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509054432"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb02727.x"},{"key":"e_1_2_1_140_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821215)50:12<2951::AID-CNCR2820501241>3.0.CO;2-S"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1"},{"key":"e_1_2_1_142_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.1987.5.3.398","article-title":"Prognosis in chronic lymphocytic leukemia: A retrospective multicentric study from the GIMEMA group","volume":"5","author":"Mandelli F","year":"1987","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_143_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.3.929.929"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07674.x"},{"key":"e_1_2_1_145_2","first-page":"273","volume-title":"European School of Oncology Monograph, Postgraduate Athens Leukemia\u2013Lymphoma Course","author":"Angelopoulou MK","year":"1997"},{"key":"e_1_2_1_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62215-0"},{"key":"e_1_2_1_147_2","first-page":"8","article-title":"What is changing in the natural history of chronic lymphocytic leukemia?","volume":"86","author":"Molica S","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_1_148_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/10428199109103403","article-title":"\u2018Smouldering\u2019 chronic lymphocytic leukemia","volume":"5","author":"Montserrat E","year":"1991","journal-title":"Leuk Lymph"},{"key":"e_1_2_1_149_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07835.x"},{"key":"e_1_2_1_150_2","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood.V75.7.1414.1414","article-title":"Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): Results of a randomized trial on 612 patients","volume":"75","author":"French Cooperative Group on Chronic Lymphocytic Leukemia F","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_151_2","first-page":"281","volume-title":"Chronic Lymphocytic Leukemia, Scientific Advances and Clinical Developments","author":"Montserrat E","year":"1993"},{"key":"e_1_2_1_152_2","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_153_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06366.x"},{"key":"e_1_2_1_154_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3263141.x"},{"key":"e_1_2_1_155_2","first-page":"373","article-title":"B\u2010chronic lymphocytic leukemia: Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern","volume":"30","author":"Pangalis GA","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_156_2","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphocytic leukemia","volume":"4","author":"Richter MN","year":"1928","journal-title":"Am J Pathol"},{"key":"e_1_2_1_157_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197802)41:2<422::AID-CNCR2820410207>3.0.CO;2-X"},{"key":"e_1_2_1_158_2","first-page":"83","volume-title":"Benign and Malignant Lymphadenopathies: Clinical and Laboratory Diagnosis","author":"Catovsky D","year":"1993"},{"key":"e_1_2_1_159_2","first-page":"117","article-title":"Chronic lymphocytic leukemia in (Richter's) transformation","volume":"25","author":"Gilles FJ","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_160_2","first-page":"207","article-title":"De novo CD5\u2010positive and Richter's syndrome\u2010associated diffuse large B\u2010cell lymphomas are genotypically distinct","volume":"147","author":"Matolcsy A","year":"1995","journal-title":"Am J Pathol"},{"key":"e_1_2_1_161_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/97.5.656"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/100.5.519"},{"key":"e_1_2_1_163_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.V64.2.571.571","article-title":"Richter's syndrome with different immunoglobulin light chains and different heavy chain gene rearrangements","volume":"64","author":"van Dongen JJM","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_164_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V58.1.183.183","article-title":"Cytogenetic evidence for the clonal nature of Richter's syndrome","volume":"5","author":"Nowell P","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800701)46:1<118::AID-CNCR2820460120>3.0.CO;2-J"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810915)48:6<1302::AID-CNCR2820480609>3.0.CO;2-Q"},{"key":"e_1_2_1_167_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1985"},{"key":"e_1_2_1_168_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199209000-00004"},{"key":"e_1_2_1_169_2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V95.3.1023.003k07_1023_1031","article-title":"Hodgkin and Reed\u2013Sterberg\u2010like cells in B\u2010cell chronic lymphocytic leukemia represent the outgrowth of single germinal\u2010center B\u2010cell\u2010derived clones: potential precursors of Hodgkin and Reed\u2013Sternberg cells in Hodgkin's disease","volume":"95","author":"Kanzler H","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02963.x"},{"key":"e_1_2_1_171_2","first-page":"262","volume-title":"American Society of Hematology Education Program Book, Hematology","author":"Keating MJ","year":"1999"},{"key":"e_1_2_1_172_2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.V59.6.1191.1191","article-title":"Staging of chronic lymphocytic leukemia","volume":"59","author":"Baccarani M","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_173_2","first-page":"275","article-title":"Prognostic and therapeutic advances in CLL management: the experience of the French Cooperative Group","volume":"24","author":"French Cooperative Group on Chronic Lymphocytic Leukemia","year":"1987","journal-title":"Semin Hematol"},{"key":"e_1_2_1_174_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08613.x"},{"key":"e_1_2_1_175_2","first-page":"363","article-title":"Comparison of the (A, B, C) staging and the Rai's staging from a large prospective series (935 patients)","volume":"30","author":"French Co\u2010operative Croup on Chronic Lymphocytic Leukemia","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_176_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01295.x"},{"key":"e_1_2_1_177_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb01149.x"},{"key":"e_1_2_1_178_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00395.x"},{"issue":"1","key":"e_1_2_1_179_2","first-page":"606a","article-title":"The serum \u03b22\u2010microglobulin (\u03b22m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL)","volume":"86","author":"Keating MJ","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_180_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01695.x"},{"key":"e_1_2_1_181_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02969.x"},{"key":"e_1_2_1_182_2","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1182\/blood.V88.11.4259.4259","article-title":"Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia","volume":"88","author":"Sarfati M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_183_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2107::AID-CNCR7>3.0.CO;2-L"},{"issue":"1","key":"e_1_2_1_184_2","first-page":"S93","article-title":"Prognostic value of LDH and \u03b22\u2010microglobulin in B\u2010CLL. Analysis of 275 patients","volume":"39","author":"Desablens B","year":"1997","journal-title":"Hematol Cell Ther"},{"issue":"1","key":"e_1_2_1_185_2","first-page":"S94","article-title":"sCD23, sCD25, serum LDH or \u03b22\u2010microglobulin\u2010what is the best prognostic factor in B\u2010CLL? Analysis of 109 patients","volume":"39","author":"Desablens B","year":"1997","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_1_186_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382104"},{"issue":"1","key":"e_1_2_1_187_2","first-page":"538a","article-title":"Circulating level of serum CD44 (sCD44) is an independent prognostic factor predicting the risk of disease\u2010progression in early B\u2010cell chronic lymphocytic leukemia","volume":"94","author":"Molica S","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_188_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V59.5.1001.1001","article-title":"Prognosis of chronic lymphocytic leukemia: A multivariate survival analysis of 150 cases","volume":"59","author":"Rozman C","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_189_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070204"},{"key":"e_1_2_1_190_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00345.x"},{"key":"e_1_2_1_191_2","first-page":"902","article-title":"Monoclonal antibody Ki\u201067 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity","volume":"2","author":"Cordone I","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_1_192_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148548"},{"key":"e_1_2_1_193_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000920)89:5<440::AID-IJC7>3.0.CO;2-U"},{"key":"e_1_2_1_194_2","first-page":"47","article-title":"Prognostic value of S\u2010phase white blood cell count in B\u2010cell chronic lymphocytic leukemia","volume":"6","author":"Orfao C","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_1_195_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb02486.x"},{"key":"e_1_2_1_196_2","doi-asserted-by":"publisher","DOI":"10.1159\/000206160"},{"issue":"1","key":"e_1_2_1_197_2","first-page":"239a","article-title":"Clinical relevance of the intensity of CD20\u2010antigen in B\u2010cell chronic lymphocytic leukemia","volume":"88","author":"Molica S","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_198_2","first-page":"369a","article-title":"Clinival relevance of circulating CD20 (cCD20) in patients with chronic lymphocytic leukemia (CLL)","volume":"96","author":"Manshouri T","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_199_2","first-page":"456","article-title":"bcl\u20102 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson LE","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_200_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4694"},{"key":"e_1_2_1_201_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.768.014k23_768_770"},{"key":"e_1_2_1_202_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01752.x"},{"key":"e_1_2_1_203_2","first-page":"795","article-title":"High levels of vascular endothelial growth factor receptor\u20102 correlated with shortened survival in chronic lymphocytic leukemia","volume":"7","author":"Ferrajoli A","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_204_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1056.bloodjournal8731056"},{"key":"e_1_2_1_205_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.256"},{"key":"e_1_2_1_206_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00358.x"},{"key":"e_1_2_1_207_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(99)00066-1"},{"key":"e_1_2_1_208_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-3-236"},{"key":"e_1_2_1_209_2","first-page":"443","article-title":"Therapy of chronic lymphocytic leukemia patients. Results from the French cooperative trials","volume":"30","author":"French Cooperative Group on Chronic Lymphocytic Leukemia","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_210_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103390"},{"key":"e_1_2_1_211_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199109103385","article-title":"Treatment of chronic lymphocytic leukemia: A preliminary report of Spanish (Pethema) trials","volume":"5","author":"Spanish Cooperative Group Pethema","year":"1991","journal-title":"Leuk Lymph"},{"key":"e_1_2_1_212_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103389"},{"key":"e_1_2_1_213_2","first-page":"754a","article-title":"UK Medical Research Council CLL3\u2010A randomized trial of the addition of epirubicin to standard chlorambucil treatment","volume":"96","author":"Catovsky D","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_214_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900060103"},{"key":"e_1_2_1_215_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_1_216_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103387"},{"key":"e_1_2_1_217_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103386"},{"key":"e_1_2_1_218_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N"},{"key":"e_1_2_1_219_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197303)31:3<502::AID-CNCR2820310303>3.0.CO;2-7"},{"key":"e_1_2_1_220_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.770"},{"key":"e_1_2_1_221_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1995.tb00244.x"},{"key":"e_1_2_1_222_2","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first\u2010line therapy in chronic lymphocytic leukemia: report of a prospective randomized, multicenter trial","volume":"96","author":"Robak T","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_223_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_1_224_2","first-page":"1135","article-title":"Long\u2010term follow\u2010up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia","volume":"85","author":"Zinzani PL","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_225_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209067614"},{"key":"e_1_2_1_226_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91681-5"},{"key":"e_1_2_1_227_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209067613"},{"key":"e_1_2_1_228_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.458"},{"key":"e_1_2_1_229_2","first-page":"218","article-title":"Fludarabine in untreated and previously treated B\u2010CLL patients: a report on efficacy and toxicity","volume":"79","author":"Spriano M","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_1_230_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400816"},{"key":"e_1_2_1_231_2","first-page":"317","article-title":"Fludarabine treatment in B\u2010cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases","volume":"84","author":"Stelitano C","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_1_232_2","first-page":"1444","article-title":"A 3\u2010day schedule of fludarabine in previously treated chronic lymphocytic leukemia","volume":"9","author":"Robertson LE","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_233_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309145882"},{"key":"e_1_2_1_234_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.22.4252"},{"key":"e_1_2_1_235_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1695.1695"},{"key":"e_1_2_1_236_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.29.29"},{"key":"e_1_2_1_237_2","first-page":"167","article-title":"Fludarabine and prednisone in pretreated and refractory B\u2010chronic lymphocytic leukemia (B\u2010CLL) in advanced stages","volume":"78","author":"De Rossi G","year":"1993","journal-title":"Haematologica"},{"key":"e_1_2_1_238_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103394"},{"key":"e_1_2_1_239_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109068099"},{"key":"e_1_2_1_240_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.3.371"},{"key":"e_1_2_1_241_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.983"},{"key":"e_1_2_1_242_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.570"},{"key":"e_1_2_1_243_2","first-page":"1130","article-title":"2\u2010Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL)","volume":"9","author":"Delannoy A","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_244_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.679"},{"key":"e_1_2_1_245_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051736"},{"key":"e_1_2_1_246_2","first-page":"349a","article-title":"2\u2010Chlorodeoxyadenosine (2\u2010CDA) in previously untreated chronic lymphocytic leukemia (CLL): preliminary analysis from the Australian Leukemia Study Group trial","volume":"86","author":"Mulligan SP","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_247_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2160"},{"key":"e_1_2_1_248_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-5-733"},{"key":"e_1_2_1_249_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1196"},{"key":"e_1_2_1_250_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.17.1416"},{"key":"e_1_2_1_251_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.433"},{"key":"e_1_2_1_252_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006100900082"},{"key":"e_1_2_1_253_2","first-page":"1346","article-title":"Effectiveness of \u2018CHOP\u2019 regimen in advanced untreated chronic lymphocytic leukemia","author":"French Cooperative Group on Chronic Lymphocytic Leukemia","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_1_254_2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.V75.7.1422.1422","article-title":"A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia","volume":"75","author":"French Cooperative Group on Chronic Lymphocytic Leukemia","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_255_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861"},{"key":"e_1_2_1_256_2","first-page":"437","article-title":"High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B\u2010CLL\u2010IGCI CLL\u201001 trial","volume":"30","author":"Jaksic B","year":"1988","journal-title":"Nouv Rev Fr Haematol"},{"key":"e_1_2_1_257_2","first-page":"127","article-title":"A randomized phase II trial of high\u2010dose chlorambucil vs. fludarabine in patients with advanced B\u2010chronic lymphocytic leukemia","volume":"41","author":"EORTC Leukemia Cooperative Group","year":"1999","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_1_258_2","first-page":"758a","article-title":"Fludarabine vs high dose chlorambucil in advanced B\u2010cell chronic lymphocytic leukemia (B\u2010CLL): results of EORTC phase\u2010II randomized trial after 4 years of median follow\u2010up","volume":"96","author":"Jaksic B","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_259_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.44"},{"key":"e_1_2_1_260_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1695.1695"},{"issue":"1","key":"e_1_2_1_261_2","first-page":"603a","article-title":"Randomized clinical trial comparing two anthracyclin\u2010containing regimens (CHOP and CAP) and fludarabine (FDR) in advanced chronic lymphocytic leukemia (CLL)","volume":"94","author":"Leporrier M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_262_2","first-page":"1167","article-title":"Fludarabine for chronic lymphocytic leukemia","volume":"344","author":"Proctor SJ","year":"2001","journal-title":"N Engl J Med"},{"key":"e_1_2_1_263_2","first-page":"259","article-title":"Multicentre prospective randomized trial of fludarabine vs chlorambucil and prednisone in previously untreated patients with active B\u2010chronic lymphocytic leukemia (B\u2010CLL): conclusive report (abstract)","volume":"84","author":"Spriano M","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_1_264_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2454"},{"key":"e_1_2_1_265_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07749.x"},{"key":"e_1_2_1_266_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049634"},{"key":"e_1_2_1_267_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.1986.4.2.128","article-title":"Clinical trial of recombinant leukocyte A interferon as initial therapy for favourable histology non\u2010Hodgkin's lymphomas and chronic lymphocytic leukemia: an Eastern Cooperative Oncology Group pilot study","volume":"4","author":"O'Connell MJ","year":"1986","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_268_2","first-page":"75","article-title":"Recombinant alpha\u20102a interferon in treatment of chronic lymphocytic leukaemia: a preliminary report with emphasis on previously untreated patients in early stage of disease","volume":"75","author":"Molica S","year":"1990","journal-title":"Haematologica"},{"key":"e_1_2_1_269_2","first-page":"471","article-title":"Randomized clinical trial with alpha\u20102b interferon in 26 stage\u2010A untreated B\u2010chronic lymphocytic leukemia patients","volume":"30","author":"Boussiotis VA","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_270_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880301)61:5<869::AID-CNCR2820610503>3.0.CO;2-I"},{"key":"e_1_2_1_271_2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.V71.5.1295.1295","article-title":"Recombinant alpha\u20102 interferon in the treatment of B chronic lymphocytic leukemia in early stages","volume":"71","author":"Rozman C","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_272_2","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.V73.6.1426.1426","article-title":"Favorable response of early stage\u2010B CLL patients to treatment with IFN\u2010\u03b12","volume":"73","author":"Ziegler\u2010Heitbrock HWL","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_273_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08115.x"},{"key":"e_1_2_1_274_2","first-page":"366","article-title":"Alpha 2\u2010interferon in B\u2010cell chronic lymphocytic leukemia: clinical response, serum cytokine levels, and immunophenotype modulation","volume":"7","author":"Morabito F","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_1_275_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08648.x"},{"key":"e_1_2_1_276_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1796.x"},{"key":"e_1_2_1_277_2","first-page":"457","article-title":"Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia","volume":"30","author":"Grever MR","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_278_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.19.bloodjournal74119"},{"key":"e_1_2_1_279_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1562"},{"key":"e_1_2_1_280_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01714952"},{"key":"e_1_2_1_281_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2878.2878"},{"key":"e_1_2_1_282_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059649"},{"key":"e_1_2_1_283_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409051694"},{"key":"e_1_2_1_284_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609093445"},{"key":"e_1_2_1_285_2","first-page":"115","article-title":"Treatment with fludarabine of chronic refractory lymphoid leukemia","volume":"40","author":"Herrero M","year":"1995","journal-title":"Sangre"},{"key":"e_1_2_1_286_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009057630"},{"issue":"1","key":"e_1_2_1_287_2","first-page":"S89","article-title":"First salvage therapy for patients relapsing or refractory after having received fludarabine for chronic lymphocytic leukaemia (CLL)","volume":"39","author":"Partyka S","year":"1997","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_1_288_2","first-page":"272","article-title":"Antiproliferative activity of 2\u2010chlorodeoxyadenosine (2\u2010CDA) in resistant lymphoid malignancies","volume":"11","author":"Tallman M","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_289_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303183281116"},{"key":"e_1_2_1_290_2","first-page":"314","article-title":"Salvage therapy with 2\u2010chlorodeoxyadenosine (2\u2010CdA) in advanced B\u2010chronic lymphocytic leukemia (CLL) is effective in patients without prior fludarabine exposure","volume":"13","author":"Rai KR","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_291_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402033300504"},{"key":"e_1_2_1_292_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008273131598"},{"key":"e_1_2_1_293_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069"},{"key":"e_1_2_1_294_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210083271504"},{"key":"e_1_2_1_295_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303183281116"},{"key":"e_1_2_1_296_2","first-page":"2","article-title":"Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross\u2010link removal","volume":"38","author":"Koel U","year":"1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_297_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"e_1_2_1_298_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401892"},{"issue":"1","key":"e_1_2_1_299_2","first-page":"313a","article-title":"Pilot study of fludarabine (F), cyclophosphamide (C), and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia (CLL)","volume":"94","author":"Keating AR","year":"1999","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_300_2","first-page":"313a","article-title":"Fludarabine plus cyclophosphamide (FC) and dose\u2010intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL): results of two phase II studies (CLL2\u2010Protocol) of the German CLL Study Group (GCLLSG)","volume":"94","author":"Hallek M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_301_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.71"},{"key":"e_1_2_1_302_2","first-page":"1268","article-title":"Low\u2010dose fludarabine and cyclophosphamide in elderly patients with B\u2010cell chronic lymphocytic leukemia refractory to conventional therapy","volume":"85","author":"Marotta G","year":"2000","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_1_303_2","first-page":"127a","article-title":"Phase II study of 2\u2010chlorodeoxyadenosine (2\u2010CDA) and cyclophosphamide (CP) in patients with chronic lymphocytic leukemia","volume":"94","author":"Montillo M","year":"1999","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_304_2","first-page":"590a","article-title":"2\u2010Chlorodeoaxyadenocine (2\u2010CdA) combined with chlorambucil (CLB) in previously untreated patients with chronic lymphocytic leukemia (B\u2010CLL)","volume":"88","author":"Tefferi A","year":"1996","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_305_2","first-page":"588a","article-title":"Fludarabine (FAMP) and mitoxantrone therapy in chronic lymphocytic leukemia (CLL)","volume":"88","author":"O'Brien S","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_306_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1069(199809)16:3<107::AID-HON630>3.0.CO;2-7"},{"key":"e_1_2_1_307_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008312432416"},{"issue":"1","key":"e_1_2_1_308_2","first-page":"198","article-title":"Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia \u2013 Preliminary results of a randomized phase\u2010III multicenter study","volume":"1","author":"Rummel MJ","year":"2001","journal-title":"Hematol J"},{"key":"e_1_2_1_309_2","first-page":"943","article-title":"Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia","volume":"9","author":"Robertson LE","year":"1995","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_1_310_2","first-page":"S88","article-title":"Combination of fludarabine, ara\u2010C, mitoxantrone and dexamethasone for the treatment of advanced chronic lymphocytic leukemia (CLL)","volume":"39","author":"Mauro FR","year":"1997","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_1_311_2","first-page":"1290","article-title":"Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia","volume":"8","author":"Weiss M","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_312_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909083393"},{"key":"e_1_2_1_313_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204115"},{"key":"e_1_2_1_314_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05225.x"},{"key":"e_1_2_1_315_2","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood.V88.6.2172.bloodjournal8862172","article-title":"Theophylline synergizes with chlorambucil in inducing apoptosis of B\u2010chronic lymphocytic leukemia cells","volume":"88","author":"Mentz F","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_316_2","doi-asserted-by":"crossref","first-page":"79a","DOI":"10.1182\/blood.V88.6.2172.bloodjournal8862172","article-title":"Synergistic effect of fludarabine and theophylline on apoptosis of B\u2010chronic lymphocytic leukemia","volume":"88","author":"Mentz F","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_317_2","first-page":"2159","article-title":"Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia","volume":"9","author":"Binet JL","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_318_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:2:99"},{"key":"e_1_2_1_319_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x"},{"key":"e_1_2_1_320_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"issue":"1","key":"e_1_2_1_321_2","first-page":"705a","article-title":"Multicenter study of Campath\u20101H in patients with chronic lymphocytic leukemia (B\u2010CLL) refractory to fludarabine","volume":"94","author":"Keating MJ","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_322_2","first-page":"163a","article-title":"Campath\u20101H is an effective salvage therapy for fludarabine failing CLL patients. Results of a phase II trial","volume":"96","author":"Rai K","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_323_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.450989.x"},{"issue":"1","key":"e_1_2_1_324_2","first-page":"603a","article-title":"Campath\u20101H therapy in 29 patients with refractory CLL: \u2018true\u2019 complete remission is an attainable goal","volume":"94","author":"Kennedy B","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_325_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1062924.x"},{"key":"e_1_2_1_326_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02826220"},{"key":"e_1_2_1_327_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_2_1_328_2","first-page":"837a","article-title":"Thrice weekly rituximab demonstrates significant activity in chronic lymphocytic leukemia","volume":"96","author":"Byrd JC","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_329_2","first-page":"514a","article-title":"Combination chemo\u2010antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL)","volume":"96","author":"Keating MJ","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_330_2","first-page":"757a","article-title":"Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)","volume":"96","author":"Garcia\u2010Manero G","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_331_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002779900141"},{"key":"e_1_2_1_332_2","first-page":"322a","article-title":"Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis CLL","volume":"92","author":"Gribben JG","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_333_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008474526373"},{"key":"e_1_2_1_334_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008308510588"},{"key":"e_1_2_1_335_2","first-page":"S54","article-title":"Fludarabine therapy followed by unmanipulated PBSCT: A single\u2010center experience on 20 CLL patients","volume":"23","author":"Proia A","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_336_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401201"},{"issue":"1","key":"e_1_2_1_337_2","first-page":"397a","article-title":"Autologous stem\u2010cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients","volume":"94","author":"Montserrat E","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_338_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.272673.x"},{"issue":"1","key":"e_1_2_1_339_2","first-page":"288a","article-title":"Allogeneic stem cell transplantation from related or unrelated donors for B\u2010cell chronic lymphocytic leukemia (B\u2010CLL)","volume":"92","author":"Pavletic ZS","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_340_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-3-199602010-00005"},{"key":"e_1_2_1_341_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008266505896"},{"key":"e_1_2_1_342_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.748"},{"key":"e_1_2_1_343_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"e_1_2_1_344_2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","article-title":"Eradication of polymerase chain reaction\u2010detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation","volume":"88","author":"Provan D","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_345_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401669"},{"key":"e_1_2_1_346_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402036"},{"key":"e_1_2_1_347_2","first-page":"482a","article-title":"Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): The EBMT experience","volume":"96","author":"Dreger P","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_348_2","first-page":"483a","article-title":"Efficacy and prognostic implications of early autologous stem cell transplantation for poor risk chronic lymphocytic leukemia","volume":"96","author":"Dreger P","year":"2000","journal-title":"Blood"},{"issue":"1","key":"e_1_2_1_349_2","first-page":"570a","article-title":"A phase I trial of bryostatin 1 in relapsed lymphoma and CLL","volume":"88","author":"Varterasain M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_350_2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood.V74.5.1747.1747","article-title":"Bryostatin 1 induces differentiation of B\u2010chronic lymphocytic leukemia cells","volume":"74","author":"Drexler HG","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_351_2","first-page":"61","article-title":"Bryostatin 1\u2010induced hairy cell features on chronic lymphocytic leukemia in vitro","volume":"21","author":"al\u2010Katib A","year":"1993","journal-title":"Exp Hematol"},{"key":"e_1_2_1_352_2","first-page":"401","article-title":"Sequential treatment of chronic lymphocytic leukemia with bryostatin 1 and \u03b1\u2010interferon","volume":"37","author":"Katato K","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"1","key":"e_1_2_1_353_2","first-page":"590a","article-title":"Sequential treatment of chronic lymphocytic leukemia (CLL) with bryostatin 1 and 2\u2010chlorodeoxyadenosine: A preclinical study","volume":"88","author":"Katato K","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_354_2","first-page":"203","article-title":"Biochemical modulation of B\u2010chronic lymphocytic leukemia with bryostatin increases sensitivity in fludarabine","volume":"37","author":"Stenson MJ","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_355_2","first-page":"2973","article-title":"Flavopiridol induces G1 arrest with inhibition of cyclin\u2010dependent kinase CDK2 and CDK4 in human breast carcinoma cells","volume":"56","author":"Carlson BA","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_1_356_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.1742"},{"issue":"1","key":"e_1_2_1_357_2","first-page":"531a","article-title":"Flavopiridol has marked in vitro activity against human B\u2010chronic lymphocytic leukemia (B\u2010CLL) and induces apoptosis independent of p53 status","volume":"90","author":"Byrd JC","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_358_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.4.1401"},{"key":"e_1_2_1_359_2","first-page":"2081","article-title":"Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN\u201001 in human breast carcinoma cells","volume":"53","author":"Seynaeve CM","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_1_360_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.14.956"},{"key":"e_1_2_1_361_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00649-X"},{"issue":"1","key":"e_1_2_1_362_2","first-page":"591a","article-title":"In vitro effects of melarsoprol as compared to arsenic trioxide (AS2O3) in chronic lymphoid malignancies","volume":"88","author":"Konig A","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_363_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1472"},{"key":"e_1_2_1_364_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2917"},{"key":"e_1_2_1_365_2","first-page":"249","volume-title":"Chronic Lymphocytic Leukemia","author":"Bunch C","year":"1988"},{"key":"e_1_2_1_366_2","first-page":"399","volume-title":"Chronic Lymphocytic Leukemia Scientific Advances and Clinical Developments","author":"Kontoyiannis DP","year":"1993"},{"key":"e_1_2_1_367_2","first-page":"374","article-title":"Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow\u2010up","volume":"78","author":"Molica S","year":"1993","journal-title":"Haematologica"},{"key":"e_1_2_1_368_2","first-page":"383","volume-title":"Chronic Lymphocytic Leukemia: Recent Progress, Future Direction","author":"Chapel H","year":"1987"},{"key":"e_1_2_1_369_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1973.03650100076014"},{"key":"e_1_2_1_370_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb01805.x"},{"key":"e_1_2_1_371_2","first-page":"291","article-title":"Mechanisms of infection in chronic lymphocytic leukemia","volume":"24","author":"Chapel HM","year":"1987","journal-title":"Semin Hematol"},{"key":"e_1_2_1_372_2","first-page":"98","article-title":"The infectious complications of chronic lymphocytic leukemia","volume":"25","author":"Morrison VA","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_373_2","first-page":"27","article-title":"Impairments in immune cell function in B cell chronic lymphocytic leukemia","volume":"25","author":"Bartik MM","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_1_374_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830190109"},{"key":"e_1_2_1_375_2","first-page":"43","article-title":"Monocyte and granulocyte defect in chronic lymphocytic leukemia","volume":"95","author":"Zeya HI","year":"1979","journal-title":"Am J Pathol"},{"key":"e_1_2_1_376_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810063191403"},{"key":"e_1_2_1_377_2","first-page":"1715","article-title":"Les infections graves associees a la leucemic lymphoide chronique. 159 episodes infectieux observes chex 60 malades","volume":"15","author":"Travade P","year":"1985","journal-title":"La Presse Med"},{"key":"e_1_2_1_378_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"key":"e_1_2_1_379_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107113250202"},{"key":"e_1_2_1_380_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260216"},{"key":"e_1_2_1_381_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05002.x"},{"key":"e_1_2_1_382_2","first-page":"121","article-title":"Prophylaxis against infections with low\u2010dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica S","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_1_383_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1995.tb00322.x"},{"key":"e_1_2_1_384_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01874.x"},{"key":"e_1_2_1_385_2","article-title":"Management of disease\u2010related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations","author":"Ludwig H","journal-title":"Hematology J"},{"key":"e_1_2_1_386_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08374.x"},{"key":"e_1_2_1_387_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009054891"},{"issue":"1","key":"e_1_2_1_388_2","first-page":"526a","article-title":"Clinical and health status assessment in anemic chronic lymphocytic leukemia (CLL) patients, treated with epoetin alfa (EPO)","volume":"84","author":"Rose E","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_389_2","article-title":"\u2018Downstaging\u2019 Rai stage III B\u2010chronic lymphocyte leukemia patients with the administration of recombinant human erythropoietin","author":"Pangalis GA","journal-title":"Haematologica"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.696","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:20:48Z","timestamp":1700389248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,26]]},"references-count":388,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1002\/hon.696"],"URL":"https:\/\/doi.org\/10.1002\/hon.696","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,26]]}}}